The prevalence of contraindications to analgesics among the long-livers aged 90+ years old

To assess the chronic pain (CP) prevalence among the long-livers, as well as both prevalence and spectrum of contraindications to non-steroidal anti-inflammatory drugs (NSAIDs) and opioids for systemic non-invasive use. The study included 1101 patients aged 90+ years old (median — 92 years) who applied for medical aid. Contraindications to analgesics were identified according to the effective versions of product labellings. CP was diagnosed in 51% of women and 52% of men. In the study population we found 1225 contraindications (mean: 2.18±0.056 per patient). The number of contraindications was significantly higher in men (2.51±0.056) compared to women (2.05±0.063, р<0.001). The contraindications to both analgesic classes were also more common in men compared to women (22.3% versus 12.5%, р<0.01). The most commonly seen contraindications corresponded to cardiovascular pathology (75% of patients). The general prevalence of contraindications to NSAIDs among the long-livers with CP was rather high (91-93%). On the contrary, the contraindications to opioids were 5-6 times less common (14-24% of patients, р<0.001). The prevalence of CP among the long-livers is 52%. The high prevalence of the contraindications to NSAIDs allows to use these drugs only in approximately 10% of patients. The contraindications to opioids were significantly less commonly seen. Up to 22.3% of long-livers with CP have contraindications to both NSAIDs and opioids and need alternative approaches to pain-relieving therapy.

1. World Population Prospects: The 2017 Revision. 21 June 2017. Available at: https://www.un.org/development/desa/ publications/world-population-prospects-the-2017-revision (accessed 02.09.2020).

2. Krause O., Junius-Walker U., Wiese B., Hager K. Werden selbst geriatrische Patienten immer älter und älter? : Veränderung der Altersstruktur geriatrischer stationär behandelter Patienten im Verlauf zweier Dekaden. Z Gerontol Geriatr, 2018, vol.51, no.1, pp.81-84. doi:10.1007/s00391-016-1162-6.

3. Varlamova M.A., Sinyavskaya O.V. Portret pozhilogo naseleniya Rossii [The portrait of the Russian Elderly Population]. Demoskop Weekly [Demoscope Weekly]. 2015, no.627–628. Available at: http://demoscope.ru/weekly/2015/0627/demoscope627.pdf (accessed 02.09.2020) (In Russian).

4. Naumov A.V., Moroz V.I., Khovasova N.O. Khronicheskaya bol' v pozhilom vozraste: fokus na sarkopeniyu [The chronic pain in the elderly: focus on sarcopenia]. Medicinsky Sovet [The Medical Council]. 2019, no.12. pp.106–114.

5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009, vol. 57, no. 8, pp. 13311346. doi:10.1111/j.1532-5415.2009.02376.x.

6. Mohamed Zaki L.R., Hairi N.N. Chronic pain and pattern of health care utilization among Malaysian elderly population: National Health and Morbidity Survey III (NHMS III, 2006). Maturitas, 2014, vol.79, no.4, pp. 435-441. doi:10.1016/j.maturitas.2014.08.014.

7. Bauer H., Emeny R.T., Baumert J., Ladwig K.H. Resilience moderates the association between chronic pain and depressive symptoms in the elderly. Eur J Pain, 2016, vol.20, no.8, pp.1253-1265. doi:10.1002/ejp.850.

8. Zanocchi M., Maero B., Nicola E.. Chronic pain in a sample of nursing home residents: prevalence, characteristics, influence on quality of life (QoL). Arch Gerontol Geriatr., 2008, v.47, no.1, p.121-128. doi:10.1016/j.archger.2007.07.003.

9. Putilina M. V. Komorbidnost' u patsientov pozhilogo vozrasta [The comorbitity in elderly patients]. S.S. Korsakov Journal of Neurology and Psychiatry, 2016, vol.116, no.5, pp.106-111. doi: 10.17116/jnevro201611651106-111.

10. Gosudarstvennyy reestr lekarstvennykh sredstv [The State Drugs Registry]. Available at: https://grls. rosminzdrav.ru/default.aspx. (Accessed 2.09.2020).

11. Kozak-Szkopek E., Broczek K., Slusarczyk P. Prevalence of chronic pain in the elderly Polish population results of the PolSenior study. Arch Med Sci. 2017, vol. 13, no. 5, pp. 1197-1206. doi:10.5114/aoms.2015.55270.

12. Jackson T., Thomas S., Stabile V., Han X., Shotwell M., McQueen K. Prevalence of chronic pain in low-income and middle-income countries: a systematic review and metaanalysis. Lancet, 2015, vol.385. suppl.2, p.S10. doi:10.1016/S0140-6736(15)60805-4.

13. Tracy B., Sean Morrison R. Pain management in older adults. Clin Ther., 2013 vol.35, no.11, pp. 1659-1668. doi:10.1016/j.clinthera.2013.09.026.

14. Karateev A.E., Nasonov E.L., Yakhno N.N. et al. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoy praktike» [Clinical guidelines ‘Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice’]. Modern Rheumatology Journal, 2015; v.9, no.1, p.4-23. https://doi.org/10.14412/1996-7012-2015-1-4-23 (In Russian).

15. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Safety Announcement. Available at: https://www.fda.gov/media/92768/download. (accessed 14.08.20).

16. Chen Y., Bedson J., Hayward R.A., Jordan K.P. Trends in prescribing of non-steroidal anti-inflammatory drugs in patients with cardiovascular disease: influence of national guidelines in UK primary care — Family Practice, 2018, v.35, iss.4, p.426–432. https://doi.org/10.1093/fampra/cmx142.

17. Kim J., Lee J., Shin C.M. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Research and Care. 2015, vol.3, p. e000133. doi: 10.1136/bmjdrc-2015-000133.

18. Hogan D.B., Campbell N.R., Crutcher R., Jennett P., MacLeod N. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. CMAJ, 1994, vol. 151(3), pp.315-322.

19. Klinicheskie rekomendatsii. Stabil'naya ishemicheskaya bolezn' serdtsa. 2020 g. [2020 Clinical guidelines Stable Ischemic Disease]. Available at: http://cr.rosminzdrav.ru/#!/schema/133 (accessed 14.08.20).

20. Keenan R.T., O'Brien W. R., Lee K. H., Crittenden D. B., Fisher M. C., Goldfarb D. S. et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am. J. Med., 2011, vol. 124, no.2, pp.155–163. doi: 10.1016/j.amjmed.2010.09.012.